Octreotide Hydrochloride
| Evidence Level: L5 | Predicted Indications: 50 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Octreotide Hydrochloride |
| DrugBank ID | DB00104 |
| Brand Names (EU) | Oczyesa |
| Evidence Level | L5 |
| Predicted Indications | 50 |
| Top Prediction Score | 99.58% |
Approved Indication (EMA)
Oczyesa is indicated for maintenance treatment in adult patients with acromegaly who have responded to and tolerated treatment with somatostatin analogues.
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | vulvar inverted follicular keratosis | 99.58% | DL |
| 2 | seborrheic keratosis | 99.55% | DL |
| 3 | nephrotic syndrome ocular anomalies | 98.84% | DL |
| 4 | Addison disease | 98.74% | DL |
| 5 | membranoproliferative glomerulonephritis, X-linked | 98.72% | DL |
| 6 | familial idiopathic steroid-resistant nephrotic syndrome with diffuse mesangial sclerosis | 98.57% | DL |
| 7 | familial idiopathic steroid-resistant nephrotic syndrome with minimal changes | 98.57% | DL |
| 8 | adrenocortical insufficiency | 98.47% | DL |
| 9 | primary hypereosinophilic syndrome | 98.43% | DL |
| 10 | autosomal recessive familial Mediterranean fever | 98.31% | DL |
| 11 | primary hereditary glaucoma | 98.23% | DL |
| 12 | secondary hypereosinophilic syndrome | 98.09% | DL |
| 13 | familial nephrotic syndrome | 98.05% | DL |
| 14 | open-angle glaucoma | 97.97% | DL |
| 15 | familial Mediterranean fever, autosomal dominant | 97.82% | DL |
| 16 | retinal telangiectasia | 97.82% | DL |
| 17 | renal-hepatic-pancreatic dysplasia | 97.70% | DL |
| 18 | Smouldering systemic mastocytosis | 97.67% | DL |
| 19 | gout | 97.53% | DL |
| 20 | lymphoadenopathic mastocytosis with eosinophilia | 97.47% | DL |
Showing top 20 of 50 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.